This book addresses the issues relating to a wide variety of ocular diseases from which millions of people suffer. Long-term challenges include visual impairment and ocular blindness. Certain ocular diseases are quite rare, whereas others, such as cataracts, age-related macular degeneration (AMD), and glaucoma, are very common, especially in the aging population. A rapid expansion of new technologies in ocular drug delivery and new drug candidates, including biologics, to treat these challenging diseases in the retina and posterior segments of the eye have recently emerged. These approaches are necessary because the eye has many unique barriers to drug delivery. Thus, this timely reference Drug Delivery for the Retina and Posterior Segment Disease compiles and analyzes recent advances in the research and development of drug delivery systems for retina and posterior segment diseases of the eye, with an emphasis on the use of implantable devices, iontophoresis as well as micro- and nanoparticles.

This book presents an overview of the rapidly developing field of nanotechnology applications in drug delivery systems and covers a variety of technologies and materials that help in achieving vast variation in the particle size needed in technology and drug delivery-based research. It discusses nanotechnology’s use in healthcare for the development of target-specific drug therapy and smart field systems and in the pharmaceutical industry to improve the quality, efficacy, and shelf life of medicines. Bringing together principles, theory, practice, and applications of nanotechnology, the book is a useful resource for chemists, physicists, biomedical researchers, engineers, advanced undergraduate and graduate-level students in nanotechnology, researchers in pharmaceutical sciences, chemistry, biology, biotechnology engineering, and general readers in nanotechnology.

This book addresses the issues relating to a wide variety of ocular diseases from which millions of people suffer. Long-term challenges include visual impairment and ocular blindness. Certain ocular diseases are quite rare, whereas others, such as cataracts, age-related macular degeneration (AMD), and glaucoma, are very common, especially in the aging population. A rapid expansion of new technologies in ocular drug delivery and new drug candidates, including biologics, to treat these challenging diseases in the retina and posterior segments of the eye have recently emerged. These approaches are necessary because the eye has many unique barriers to drug delivery. Thus, this timely reference Drug Delivery for the Retina and Posterior Segment Disease compiles and analyzes recent advances in the research and development of drug delivery systems for retina and posterior segment diseases of the eye, with an emphasis on the use of implantable devices, iontophoresis as well as micro- and nanoparticles. .

There have been major advancements in the pharmacologic treatment of eye diseases over the past decade. With newly discovered disease targets and novel approaches to deliver therapeutic compounds to the eye, patients are seeing improved outcomes. Not only are there better treatments for diseases where treatments existed, we now have effective therapy for previously untreatable and blinding eye disorders. This volume will cover the pharmacologic treatment of eye diseases from the front of the eye including eyelids, conjunctiva and cornea all the way back to the retina and optic nerve. The first section of the volume reviews general principles of ocular pharmacology, pharmacokinetics, pharmaceutical sciences, and drug delivery. In addition, the volume provides an up to date guide to the pharmacologic approach to the key eye diseases that threaten sight or ocular function.

This book delves into the field of immobilizing biologically active and non-active molecules. It discusses the designing strategy of immobilization and the current state-of-the-art applications for advancing biomedical, agricultural, environmental and industrial practices. It focuses on aspects ranging from fundamental principles to current technological advances at multi-scale levels (macro, micro, and nano) which are suitable for cell, enzyme, and nano-catalyst based applications. Written by experts from across the globe, the contents deal with illustrated examples of molecular and cellular interactions with materials/scaffolds and discussions on factors that can affect the functionality and yield of the process. With its discussions on material science, design of delivery vehicles, separation science, additive manufacturing, agriculture and environmental science, this book will be a useful reference for researchers across multiple disciplines.

This comprehensive volume discusses approaches for a systematic selection of delivery systems for various classes of therapeutic agents including small molecule, protein, and nucleic acid drugs. Specific topics covered in this book include: Solution, suspension, gel, nanoparticle, microparticle, and implant dosage forms Refillable and microneedle devices Intravitreal, suprachoroidal, intrascleral, transscleral, systemic, and topical routes of delivery Physical methods including iontophoresis for drug delivery Rational selection of routes of administration and delivery systems Noninvasive and continuous drug monitoring Regulatory path to drug product development Clinical endpoints for drug product development Emerging and existing drugs and drug targets Drug Product Development for the Back of the Eye is authored by renowned ocular drug delivery experts, representing academic, clinical, and industrial organizations and serves as indispensable resource for ophthalmic researchers, drug formulation scientists, drug delivery and drug disposition scientists, as well as clinicians involved in designing and developing novel therapeutics for the back of the eye diseases. This book is also relevant for students in various disciplines including ophthalmology, pharmaceutical sciences, drug delivery, and biomedical engineering. Refillable and microneedle devices Intravitreal, suprachoroidal, intrascleral, transscleral, systemic, and topical routes of delivery Physical methods including iontophoresis for drug delivery Rational selection of routes of administration and delivery systems Noninvasive and continuous drug monitoring Regulatory path to drug product development Clinical endpoints for drug product development Emerging and existing drugs and drug targets Drug Product Development for the Back of the Eye is authored by renowned ocular drug delivery experts, representing academic, clinical, and industrial organizations and serves as indispensable resource for ophthalmic researchers, drug formulation scientists, drug delivery and drug disposition scientists, as well as clinicians involved in designing and developing novel therapeutics for the back of the eye diseases. This book is also relevant for students in various disciplines including ophthalmology, pharmaceutical sciences, drug delivery, and biomedical engineering. Refillable and microneedle devices Intravitreal, suprachoroidal, intrascleral, transscleral, systemic, and topical routes of delivery Physical methods including iontophoresis for drug delivery Rational selection of routes of administration and delivery systems Noninvasive and continuous drug monitoring Regulatory path to drug product development Clinical endpoints for drug product development Emerging and existing drugs and drug targets Drug Product Development for the Back of the Eye is authored by renowned ocular drug delivery experts, representing academic, clinical, and industrial organizations and serves as indispensable resource for ophthalmic researchers, drug formulation scientists, drug delivery and drug disposition scientists, as well as clinicians involved in designing and developing novel therapeutics for the back of the eye diseases. This book is also relevant for students in various disciplines including ophthalmology, pharmaceutical sciences, drug delivery, and biomedical engineering.

Applications of Nanovesicular Drug Delivery provides thorough insights and a complete and updated discussion on the preparation, properties and drug delivery applications of various nanovesicles. This volume will discuss target-specific drug application, such as ocular, transdermal, nasal, intravenous and oral delivery. This title is a valuable resource for academics, pharmaceutical scientists, including industrial pharmacists and analytical scientists, health care professionals and regulatory scientists actively involved in pharmaceutical products and process development of tailored-made polysaccharides in drug delivery applications. Recently, there have been a number of outstanding nanosystems in nanovesicular carrier-forms (such as nanoemulsions, self-nanoemulsifying systems, nanoliposomes, nanotransferosomes, etc.), that have been researched and developed for efficient drug delivery by many formulators, researchers and scientists. However, no previously published books have covered all these drug delivery nanovesicles collectively in a single resource. - Provides thorough insights and up-to-date discussions about the various systems of nanovesicular drug delivery - Covers advanced trigger-assisted systems (such as iontophoresis, ultra-sound triggering, etc.) and how they have been used for improved drug delivery by nanovesicles - Presents recent advances in drug delivery fields by global leaders and experts from academia, research, industry and regulatory agencies - Includes an updated literature review of relevant key topics, good quality illustrations, chemical structures, attractive flow charts and well-organized tables

This book reviews the current state of ocular drug therapy and future therapeutic opportunities for a wide variety of conditions, including Age-related Macular Degeneration, Diabetic Retinopathy and Macular Edema, Glaucoma, and Inherited Retinal Diseases. Retinal diseases are major contributors to moderate or severe vision impairment in adults aged 50 years and older. The respective patient populations for many of these indications is expected to significantly increase as the world population continues to grow older. An improved understanding of the etiological underpinnings of ocular degenerative diseases over the past decade has significantly bolstered ophthalmic drug discovery. In this volume, contributions from leading experts explore the unique challenges faced for ocular drug discovery and delivery providing the reader with detailed information on ocular pharmacokinetics, in vitro, ex vivo and in vivo models for retinal disease pathology and emerging gene therapy treatments. The book is intended for all researchers and clinicians who wish to increase their knowledge on the latest findings in ocular drug therapy.

Drug discovery for ocular diseases has taken great strides in the last two decades. From cornea to choroid, new drugs have been formulated to address a great variety of ocular diseases. Yet without good drug delivery systems, these drugs are less effective than they might be or could even cause serious side effects. Ocular Drug Delivery Systems: Ba

The eye is the most easily accessible site for topical administration of a medication. Drugs are commonly applied to the eye for localised action on the surface or in the interior of the eye. A major problem in ocular therapeutics is the attainment of an optimal drug concentration at the site of action. Poor bioavailability of drugs from ocular dosage forms is mainly due to the precorneal loss factors which include tear dynamics, non-productive absorption, transient residence time in the cul-de-sac, and the relative impermeability of the corneal epithelial membrane. Due to these physiological and anatomical constraints only a small fraction of the drug, effectively 1% or even less of the instilled dose is ocularly absorbed. The effective dose of medication administered ophthalmically may be altered by increasing the retention time of medication in contact with the surface of the eye. To date, Pharmaceutical Technologists have tried to develop different novel formulations like gel, ocular inserts, collagen shields, implants, liposomes, nanoparticles, penetration enhancers and in-situ gelling systems, in order to increase the bioavailability and duration of the therapeutic action of ocular drugs and polymers plays an important role in all these approaches. This book provides detailed information regarding all such polymers which have been used and shown to be excellent in improving the bioavailability of ocular drugs.